Related Experiment Videos

Alternative pathway complement activation in rheumatoid arthritis

Insights

Rheumatoid arthritis (RA) shows increased alternative pathway complement turnover, indicated by lower factor B and properdin levels in synovial fluid. However, C3b inactivator levels were reduced, suggesting it doesn't control this pathway's activity in RA.

Area of Science:

  • Immunology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation.
  • The complement system, particularly the alternative pathway, plays a role in RA pathogenesis.
  • Understanding complement component levels in synovial fluid is crucial for RA research.

Purpose of the Study:

  • To investigate the levels of complement components in the synovial fluid of RA patients.
  • To determine the involvement of the alternative complement pathway in RA.
  • To assess the role of C3b inactivator and beta 1H in regulating complement turnover in RA.

Main Methods:

  • Measurement of serum and synovial fluid (SF) complement components (C3, C5, factor B, properdin, beta 1H, C3b inactivator).
  • Quantification of SF C3d and Ba concentrations.
  • Comparison of levels between 40 RA patients and 5 osteoarthritis patients.

Main Results:

  • Decreased SF concentrations of factor B and properdin were observed in RA patients.
  • Increased SF Ba levels indicated enhanced alternative pathway turnover in RA.
  • Reduced SF C3b inactivator concentrations were found, while beta 1H levels remained unchanged.

Conclusions:

  • Increased alternative pathway turnover occurs in rheumatoid arthritis.
  • Alternative pathway turnover in RA is dependent on C3 turnover.
  • Reduced C3b inactivator levels in RA do not appear to control alternative pathway turnover.

Related Concept Videos